Targeting two alternate pathways at the same time led to improved outcomes in multiple preclinical models of advanced breast cancer.
Commentary|Articles|May 2, 2025
Oncology Experts Highlight Top Takeaways From the 2025 AACR Annual Meeting
Author(s)Ashling Wahner
Fact checked by: Jax DiEugenio
Experts from across oncology specialties shared some of the most talked-about abstracts and discussions from the 2025 AACR Annual Meeting.
Advertisement
Advertisement
Following the
Related to this article
Updated LEGEND cohort 1 data showed a 56% CR rate and a 24% 12-month CR rate with detalimogene in BCG-unresponsive, high-risk NMIBC with CIS.
Phase 2 Co-PSMA data showed higher lesion detection with 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11 in biochemical recurrence after prostatectomy.
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses CLL17 trial data, resistance mechanisms, and emerging BTK degraders and bispecifics in CLL.
Check out this October recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.
Thomas Powles, MBBS, MRCP, MD, discusses LITESPARK-022 QOL findings and patient selection for adjuvant belzutifan plus pembrolizumab in RCC.
Gov. Hochul unveils a cell and gene therapy fellowship between Roswell Park and San Juan City Hospital to train Puerto Rico physicians in advanced cancer care.
Retrospective data tie longer survival with niraparib maintenance to homologous recombination deficiency after complete primary debulking.
Advertisement
Advertisement